Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-04991532 And Sitagliptin In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin

NCT01336738 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01336738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01336738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-04991532 And Sitagliptin In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
March 31, 2012
Enrollment
266 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, type 2